Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended increasing the dose to 10 mg/kg for Cohort 2 in its ELEVATE-45-201 Phase 1/2 trial for Duchenne muscular dystrophy. This follows safety and pharmacokinetic reviews of Cohort 1 participants dosed at 5 mg/kg. The trial evaluates ENTR-601-45, targeting patients amenable to exon 45 skipping, with dosing every six weeks. Entrada plans to report Cohort 1 data mid-2026, with subsequent data from higher doses to follow, aiming to improve patient outcomes and reduce treatment burden.
YieldMax® has declared monthly distributions for its Target 12™ ETFs, aiming for a 12% annual income. The ETFs include BIGY, RNTY, and SOXY, each with varying distribution rates and risks such as price participation limits and liquidity concerns. Inv...
Questrade has introduced Custom Indexing, Canada's first personalized index investing product that allows investors to create tailored index portfolios without management or trading fees. Investors can customize their portfolios by selecting from a b...
The European Union is set to propose tighter regulations for cloud computing services in major state tenders, aiming to reduce reliance on U.S. tech giants like Amazon, Microsoft, and Google. This move is part of the EU's Cloud and AI Development Act...
The global Mass Notification System (MNS) market is forecasted to grow from $28.88 billion in 2025 to $80.44 billion by 2030, at a CAGR of 22.7%. This surge is driven by stricter regulatory requirements for multi-channel emergency communication and t...
The global peripheral vascular devices market is projected to grow from $10.02 billion in 2026 to $13.22 billion by 2031, at a CAGR of 5.7%. Growth is fueled by rising cases of vascular disorders linked to aging, diabetes, and lifestyle factors, alon...
